Helix Biomedix Inc
Other Technology · Bothell, Washington
Helix Biomedix Inc is a other technology company based in Bothell, Washington. It has raised at least $16.6 million across 1 known rounds, of which $5.6 million was reported to the SEC on 1 Form D filing, most recently in 2019.
Where Biotech Meets Breakthroughs A biotechnology company focused on innovative drug discovery and development targeting Xeroderma Pigmentosum. Learn More Helix BioMedix merges science and care to create innovative dermatologic treatments. We’re transforming skin health with precision, safety and purpose. Disease Focus Xeroderma Pigmentosum (XP) Helix BioMedix is advancing preclinical research for
| Date | Round | Amount | Raised to date | Lead investor | Source |
|---|---|---|---|---|---|
| 2019-07-30 | — | $5.6M | $16.6M | SEC Form D | |
| 2014-12-03 | — | $1.0M | $11.0M | SEC Form D | |
| 2013-05-01 | — | $500K | $10.0M | SEC Form D | |
| 2011-01-07 | — | $600K | $9.5M | SEC Form D | |
| 2011-01-07 | — | $6.0M | $8.9M | SEC Form D | |
| 2010-03-12 | — | $2.9M | $2.9M | SEC Form D |
SEC rows are Form D filings, where the amount is what was actually sold and amendments update a round rather than adding one. Press rows are split between company-issued releases or wires and editorial or third-party coverage. The total is therefore a floor: a round nobody reported is a round we cannot see. A buyout or control change appears in the timeline but is never added to the total: that money goes to shareholders, not into the company.
Form D is the notice a company files with the SEC when it sells securities without registering them. It reports the amount sold, not a valuation. Figures here are what the filing says. Where a filing is silent, the field is left blank rather than estimated. “Total raised” adds press-reported rounds that never appear in a filing, so it is a floor rather than an audited sum: press amounts are the figures the company announced, and a round nobody reported is a round we cannot see.